Clinical Trials Logo

Filter by:
NCT ID: NCT05605704 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Olive Leaf Extracts in the Control of Diabet

Dia-Athr
Start date: January 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital). Patients over 18 years of age with: -Diabets

NCT ID: NCT05603130 Completed - COVID-19 Disease Clinical Trials

Epidemiologic Register on Diabetes and COVID-19 in Tunisia

Start date: March 23, 2022
Phase:
Study type: Observational [Patient Registry]

CoviDTUN is a multicenter observatory set up by a steering committee to determine the presentation and evolution of diabetes in COVID-19 and study its pathogenesis. The observatory comprises a dataset consisting of routinely collected clinical information anonymously to be entered by the investigator as a participating clinician/researcher. The study will be an opportunity to understand the relationship between COVID-19 and diabetes, to enrich Tunisian data on diabetic and de novo diabetic patients who have contracted COVID-19 and to evaluate the prognostic severity factors for better management of these patients.

NCT ID: NCT05577650 Completed - Diabetes Mellitus Clinical Trials

Prevalence of Chronic Kidney Disease in Tunisian Diabetics

TUN-CKDD
Start date: January 9, 2023
Phase:
Study type: Observational

In Tunisia, diabetes is a serious public health problem, its prevalence reaches 22.9% of people aged 18 and over and is likely to affect a quarter of the population by 2045. Diabetic kidney disease is the most common and severe complication of diabetes. It is both a major cause of end-stage renal disease and a risk factor for mortality and cardiovascular morbidity, thus becoming an additional public health concern. Early diagnosis of diabetic kidney disease makes it possible to manage patients more effectively and in a multidisciplinary way, to delay its progression to chronic renal failure.

NCT ID: NCT05560841 Completed - Onychomycosis Clinical Trials

Effectiveness and Safety of Nailner Brush 2in1 in Onychomycosis

Start date: July 28, 2022
Phase: N/A
Study type: Interventional

Evaluate the effectiveness of Nailner Brush 2-in-1 in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface after 6 months of treatment compared to baseline.

NCT ID: NCT05547646 Completed - Critical Care Clinical Trials

The Prevalence of Healthcare-associated Infection in Medical Intensive Care Units in Tunisia

NOSOREA2
Start date: September 27, 2022
Phase:
Study type: Observational

We aimed to determine the prevalence of HAI in medical Tunisian ICUs. Secondary endpoints were to identify the predominant infecting microorganisms and evaluate independent risk factors of HAIs.

NCT ID: NCT05540600 Recruiting - Atrial Fibrillation Clinical Trials

Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: Digoxin Versus Beta Blocker

Start date: September 12, 2022
Phase: Phase 3
Study type: Interventional

ß blocker and digoxin effect on left atrium reservoir function are unknown. This is a randomized open label study to compare the effect of theses two molecules on left atrium function

NCT ID: NCT05535036 Completed - Postoperative Pain Clinical Trials

Intravenous Dexamethasone Effectiveness in Post Caesarean Section Analgesia

Start date: February 10, 2020
Phase: N/A
Study type: Interventional

The management of postpartum pain is essential to ensure early rehabilitation for parturients. Intravenous dexamethasone has a potent analgesic action when used in the context of general anesthesia. Nevertheless, it remains poorly studied in combination with spinal anesthesia (SA). The aim of this study was to assess the analgesic effect of intravenous dexamethasone after caesarean section under SA. Methods: We conducted a prospective, randomized, double-blinded study including 84 ASA II-III parturient at term who were proposed for caesarean section under SA. Parturient were randomized into two groups: Dexamethasone group (DG) who received 8mg of intravenous dexamethasone (2ml) immediately after SA and placebo group (PG) who received 2ml of isotonic saline. The analgesic protocol was standardized and we opted for Tramadol as rescue analgesic. The main outcome is the use of Tramadol in the first 24 hours postpartum..

NCT ID: NCT05516446 Recruiting - Clinical trials for Coronary Artery Disease (CAD)

Drug Eluting Balloon Angioplasty Versus Everolimus Platinum Chrome Stent

DEBATE
Start date: August 25, 2021
Phase: N/A
Study type: Interventional

Randomized, open-label, single-center, non-inferiority clinical trial to compare late lumen loss (LLL) at 12 months in Tunisian population undergoing coronary percutaneous intervention between Drug Eluting Balloon treated group and Everolimus platinum chrome stent treated group.

NCT ID: NCT05516173 Recruiting - Hypertension Clinical Trials

Role of Depression in Blood Pressure Control. Study

TUN-BP-BLUE
Start date: August 15, 2022
Phase:
Study type: Observational

Our study aims to evaluate the role of depression in blood pressure control in ambulatory hypertensive patients.

NCT ID: NCT05514925 Recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy

Start date: November 21, 2017
Phase: Phase 4
Study type: Interventional

Pars-plana vitrectomy (PPV) is the cornerstone of surgical treatment for eyes with complicated proliferative diabetic retinopathy. Anti-VEGF intravitreal injection before PPV has shown a good effect on surgical outcomes. However, many patients present with co-morbidities that contraindicate the usage of anti-VEGF in the pre-operative period. Thus, cryoapplication, an old therapeutic tool for proliferative diabetic retinopathy may be a good alternative. The investigators present herein a comparative study between peripheral retinal cryoapplication and anti-VEGF before vitrectomy for complicated proliferative diabetic retinopathy.